APVO - Aptevo Therapeutics Stock Trading

Advances Phase 1/1b Clinical Trial of APVO436 for the Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Cohort 6 Enrollment Ongoing Reports Preliminary Evidence of a Potential Clinical Response Observed with APVO436 Sharpens Focus on Novel ADAPTI...

SEATTLE, WA / ACCESSWIRE / April 14, 2020 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, today announced that it has received notice from The N...

Aptevo Therapeutics (NASDAQ: APVO ): FY GAAP EPS of -$1.09 beats by $0.04 . More news on: Aptevo Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...